Information about the NUVAXOVID^TM COVID-19 Vaccine, adjuvanted [SARS-CoV-2 rS (NVX-CoV2373)]

This vaccine has provisional registration in New Zealand for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older as a primary series, 2 dose course or as a booster dose in individuals 18 years of age and older, 6 months after the completion of a primary series. The decision has been made on the basis of short-term efficacy and safety data. Continued registration depends on the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment. The use of this vaccine should be in accordance with official recommendations.